Abstract：
Aim: To perform a cost-effectiveness analysis comparing axicabtagene ciloleucel (axi-cel) with standard of care (SoC; salvage chemoimmunotherapy, followed by high-dose therapy with autologous stem cell rescue for responders) for second-line (2L) treatment of adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) in the pivotal ZUMA-7 trial data from a Japanese payer perspective. Materials & methods: A three-state partitioned survival model was utilized using population and clinical inputs from the ZUMA-7 trial data over a lifetime horizon. Results: Axi-cel was associated with greater incremental quality-adjusted life-years (2.06) and higher incremental total costs ($48,685.59/¥6.9 million) leading to an incremental cost-effectiveness ratio of $23,590.34/¥3.3 million per quality-adjusted life-years compared with SoC. Conclusion: Axi-cel is a cost-effective treatment alternative to SoC for 2L treatment of adults with r/r LBCL.
[Box: see text].
[Box: see text].
摘要：
目的：进行成本效益分析，比较axicabtageneciloleucel（axi-cel）与标准护理（SoC；挽救性化学免疫疗法，从日本付款人的角度来看，在关键的ZUMA-7试验数据中，对复发或难治性大B细胞淋巴瘤（r/rLBCL）的成人进行二线（2L）治疗。材料和方法:使用来自寿命范围内的ZUMA-7试验数据的群体和临床输入,利用三状态分区生存模型。结果：Axi-cel与更高的增量质量调整寿命年（2.06）和更高的增量总成本（48,685.59美元/69万日元）相关，导致每个质量调整寿命年的增量成本效益比为23,590.34美元/330万日元。结论：Axi-cel是一种替代SoC的具有成本效益的治疗方法，用于2L治疗成人r/rLBCL。
[方框：见正文]。
[方框：见正文]。
